Stock listing

Amneal Pharmaceuticals, Inc.

Selected listing: 2DT · SWB · EUR · DE

Amneal Pharmaceuticals, Inc. (Stuttgart:2DT), Health Technology. Latest release Sep 18, 2026: Amneal Announces FDA Approval and Launch of Lanreotide Injection.

2DT:SWBEURDEUpdated October 3, 2026

Ticker: Stuttgart:2DT
Asset type: Stock
Sector: Health Technology
Industry: Pharmaceuticals: Major
Exchange: Stuttgart
Currency: EUR

About Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals, Inc. (ticker: AMRX) is a public company operating in the American market. The company aims to provide high-quality, affordable medications to improve patient access and health outcomes.

Latest news from Amneal Pharmaceuticals, Inc.

Amneal Announces FDA Approval and Launch of Lanreotide Injection

September 18, 2026

Amneal Completes Acquisition Of Kashiv

August 17, 2026

Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader

August 10, 2026

Amneal Reports Second Quarter 2026 Financial Results

July 29, 2026

Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations

July 17, 2026

All Amneal Pharmaceuticals, Inc. news →

Events

Replays

Amneal Pharmaceuticals, Inc. (AMRX) Q2 2026 Earnings Call
Thu, Jul 30, 2026 · 08:30 AM ET
Watch
Amneal Pharmaceuticals, Inc. (AMRX) Q1 2026 Earnings Call
Fri, May 01, 2026 · 08:30 AM ET
Watch
Amneal Pharmaceuticals, Inc. (AMRX) Q4 2025 Earnings Call
Fri, Feb 27, 2026 · 08:30 AM ET
Watch

Research Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals, Inc. company profile

View the public company page for Amneal Pharmaceuticals, Inc. on 6ix.

Amneal Pharmaceuticals, Inc. news

Read company news and market updates connected to Amneal Pharmaceuticals, Inc..

Amneal Pharmaceuticals, Inc. investor events

Find investor webinars, events, and replay context for Amneal Pharmaceuticals, Inc..